Clinical data | |
---|---|
Trade names | Aredia, Pamimed, among others |
Other names | Pamidronate disodium pentahydrate, pamidronate disodium |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a601163 |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | 54% |
Metabolism | Nil |
Elimination half-life | 28 ± 7 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.049.897 |
Chemical and physical data | |
Formula | C3H11NO7P2 |
Molar mass | 235.069 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.
It was patented in 1971 and approved for medical use in 1987.[1]